| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 6.1 | $0-$5k | 0.00 |
Summary
A vulnerability identified as critical has been detected in Oracle Agile PLM 9.3.6. This impacts an unknown function of the component Security. The manipulation leads to an unknown weakness. This vulnerability is documented as CVE-2021-41184. The attack can be initiated remotely. There is not any exploit available. You should upgrade the affected component.
Details
A vulnerability was found in Oracle Agile PLM 9.3.6 (Product Lifecycle Management Software) and classified as critical. This issue affects some unknown functionality of the component Security. Using CWE to declare the problem leads to CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. Impacted is confidentiality, and integrity.
The weakness was released 07/19/2022 as Oracle Critical Patch Update Advisory - July 2022. The advisory is shared at oracle.com. The identification of this vulnerability is CVE-2021-41184. It demands that the victim is doing some kind of user interaction. Neither technical details nor an exploit are publicly available. MITRE ATT&CK project uses the attack technique T1059.007 for this issue.
The vulnerability scanner Nessus provides a plugin with the ID 211078 (Fedora 37 : drupal7 (2022-c4334d5277)), which helps to determine the existence of the flaw in a target environment.
Upgrading eliminates this vulnerability. A possible mitigation has been published immediately after the disclosure of the vulnerability.
The vulnerability is also documented in the databases at Tenable (211078) and CERT Bund (WID-SEC-2023-1015). Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
Affected
- Oracle Health Sciences Applications
Product
Type
Vendor
Name
Version
License
Website
- Vendor: https://www.oracle.com
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 6.2VulDB Meta Temp Score: 6.1
VulDB Base Score: 6.1
VulDB Temp Score: 5.8
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 6.1
NVD Vector: 🔍
CNA Base Score: 6.5
CNA Vector: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
NVD Base Score: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Nessus ID: 211078
Nessus Name: Fedora 37 : drupal7 (2022-c4334d5277)
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: UpgradeStatus: 🔍
Reaction Time: 🔍
0-Day Time: 🔍
Exposure Time: 🔍
Patch: github.com
Timeline
09/15/2021 🔍07/19/2022 🔍
07/19/2022 🔍
07/20/2022 🔍
12/08/2025 🔍
Sources
Vendor: oracle.comAdvisory: Oracle Critical Patch Update Advisory - July 2022
Status: Confirmed
CVE: CVE-2021-41184 (🔍)
GCVE (CVE): GCVE-0-2021-41184
GCVE (VulDB): GCVE-100-204521
CERT Bund: WID-SEC-2023-1015 - Oracle Health Sciences Applications: Mehrere Schwachstellen
Entry
Created: 07/20/2022 08:17Updated: 12/08/2025 11:40
Changes: 07/20/2022 08:17 (39), 08/14/2022 19:33 (3), 11/17/2024 15:01 (16), 04/30/2025 14:07 (3), 11/04/2025 18:34 (30), 12/08/2025 11:40 (7)
Complete: 🔍
Cache ID: 216::103
Several companies clearly confirm that VulDB is the primary source for best vulnerability data.
No comments yet. Languages: en.
Please log in to comment.